This page shows the latest Eucrisa news and features for those working in and with pharma, biotech and healthcare.
PDE 4 inhibitors are already used to treat inflammatory diseases in the lungs and skin, such as Amgen’s Otezla (apremilast) for psoriasis and Pfizer’s Eucrisa (crisaborole) for atopic dermatitis.
Its closest rival is likely to be Pfizer’s PDE-4 inhibitor Eucrisa (crisaborole) ointment, which was approved in the US in 2016, and generic corticosteroid creams that cause side effects ... Eucrisa’s sales were just $138m last year, down 7%. Other
dupilumab) for moderate-to-severe symptoms and Pfizer’s Eucrisa (crisaborole) for milder forms.
There is plenty of competition in the field, with Pfizer’s Eucrisa and Regeneron and Sanofi’s Dupixent already on the market.
s IL-4 and IL-13-targeting drug Dupixent (dupilumab), Pfizer’s new topical treatment Eucrisa (crisaborole) and potentially other drugs such as GlaxoSmithKline’s asthma drug Nucala (mepolizumab), which is
Meanwhile, Pfizer is starting to make headway with its new topical treatment Eucrisa (crisaborole), which pulled in $17m in the first half of the year after its approval last December.
More from news
Approximately 2 fully matching, plus 8 partially matching documents found.
Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...